Friday May 12, 2023
| 7:00 – 8:00 | Breakfast | |
| 8:00 – 8:05 | Welcome to CMHCC | Dr. Brandon Meyers (ON) |
| 8:05 – 10:00 | Early Stage Disease | Chair: Dr. Chaya Shwaartz (ON) |
| 8:05 – 8:20 | The Change in the BCLC Criteria | Dr. Robert Grant (ON) |
| 8:20 – 8:25 | Question and Answer Period with Audience | |
| 8:25 – 8:55 | Resection- Where to Draw the Line | Dr. Daniel Azoulay (France) |
| 8:55 – 9:05 | Question and Answer Period with Audience | |
| 9:05 – 9:20 | Transplant – Is There Room for Transplant in Early-Stage HCC? | Dr. Chaya Shwaartz (ON) |
| 9:20 – 9:25 | Question and Answer Period with Audience | |
| 9:25 – 9:40 | Non-Surgical Techniques for Curative Intent | Dr. John Kachura (ON) |
| 9:40 – 9:45 | Question and Answer Period with the Audience | |
| 9:45 – 10:05 | Early Stage Disease Panel Discussion/Cases with Audience | Chair: Dr. Chaya Shwaartz, Panel: Dr. Daniel Azoulay, Dr. Michael Lock, Dr. Robert Grant, Dr. Trevor Reichman |
| 10:05 – 10:30 | Refreshment Break | |
| 10:30 – 12:00 | Intermediate/Locally Advanced Stage Disease | Chair: Dr. Anand Swaminath (ON) |
| 10:30 – 10:35 | Welcome and Introductions ( Pre Debate Vote) | Dr. Anand Swaminath |
| 10:35 – 11:10 | Debate: Y90 vs External Beam RT | Dr. Michael Lock and Dr. David Liu |
| 10:35 – 10:45 | Y 90 | Dr. David Liu (BC) |
| 10:45 – 10:55 | External Beam RT | Dr. Michael Lock (ON) |
| 10:55 – 11:05 | Rebuttals | Dr. Michael Lock and Dr. Dave Liu |
| 11:05 – 11:10 | Voting/ Discussion with Audience | |
| 11:10 – 11:45 | Case Based Panel Discussion with Audience | Chair: Dr. Anand Swaminath, Panel: Dr. Michael Lock, Dr. David Liu, Dr. Brandon Meyers, Dr. Chaya Shwaartz |
| 11:45 – 13:00 | Lunch | |
| 13:00 – 16:00 | Afternoon Sessions | Dr. Vincent Tam (AB) |
| 13:05 – 13:50 | Keynote: Advents in the Treatment of Hepatocellular Carcinoma. Where Are We Going? | Dr. Ghassan Abou-Alfa (NY, USA) |
| 13:50 – 14:05 | Question and Answer Period | |
| 14:05 – 14:25 | Refreshment Break | |
| 14:25 – 16:10 | Advanced Stage Disease | Chair: Dr. Rachel Goodwin (ON) |
| 14:25 – 14:45 | Trial Review | Dr. Ravi Ramjeesingh (NS) |
| 14:45 – 14:50 | Question and Answer Period | |
| 14:50 – 15:20 | Debate: Dual Immunotherapy versus Checkpoint Inhibitor + VEGF Inhibitor in First-Line Treatment of HCC |
Dual Immunotherapy -Dr. Vincent Tam Checkpoint Inhib. + VEGF – Dr. Brandon Meyers |
| 15:20 – 15:40 | Voting and Question Period with the Audience | |
| 15:40 – 16:10 | Advanced Stage Panel Discussion with Audience | Chair: Dr. Rachel Goodwin, Panel: Dr. Ghassan Abou-Alfa, Dr. Jennifer Knox, Dr. Vincent Tam, Dr. Anand Swaminath |
| 16:10 – 16:15 | Closing Remarks | Dr. Vincent Tam |